UGT1A1*28 polymorphism and the risk of toxicity and disease progression in patients with breast cancer receiving sacituzumab govitecan

UGT1A1*28 polymorphism and the risk of toxicity and disease progression in patients with breast cancer receiving sacituzumab govitecan

Abstract Background Sacituzumab govitecan (sacituzumab) emerged as an important agent in metastatic and locally recurrent HER2‐negative breast cancer treatment. UGT1A1 polymorphisms have also been shown to predict sacituzumab toxicity. Methods In this retrospective study, we sought to evaluate the a...

Full description

Saved in:
Bibliographic Details
Main Authors: Megan H. Wong, Veronica C. Jones, Wai Yu, Linda D. Bosserman, Sayeh M. Lavasani, Niki Patel, Mina S. Sedrak, Daphne B. Stewart, James R. Waisman, Yuan Yuan, Joanne E. Mortimer
Format: Article
Language:English
Published: Wiley 2024-08-01
Series:Cancer Medicine
Subjects:
metastatic breast cancer
pharmacogenetics
sacituzumab govitecan
SN‐38 toxicity
UGT1A1*28
Online Access:https://doi.org/10.1002/cam4.70096
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/cam4.70096

Similar Items